190 related articles for article (PubMed ID: 36104354)
21. 13q12.2 deletions in acute lymphoblastic leukemia lead to upregulation of FLT3 through enhancer hijacking.
Yang M; Safavi S; Woodward EL; Duployez N; Olsson-Arvidsson L; Ungerbäck J; Sigvardsson M; Zaliova M; Zuna J; Fioretos T; Johansson B; Nord KH; Paulsson K
Blood; 2020 Aug; 136(8):946-956. PubMed ID: 32384149
[TBL] [Abstract][Full Text] [Related]
22. ZNF384-fusion proteins have high affinity for the transcriptional coactivator EP300 and aberrant transcriptional activities.
Yamamoto H; Hayakawa F; Yasuda T; Odaira K; Minamikawa Y; Tange N; Hirano D; Kojima Y; Morishita T; Tsuzuki S; Naoe T; Kiyoi H
FEBS Lett; 2019 Aug; 593(16):2151-2161. PubMed ID: 31234226
[TBL] [Abstract][Full Text] [Related]
23. ZNF384 fusion transcript levels for measurable residual disease monitoring in adult B-cell acute lymphoblastic leukemia.
Shi ZY; Wang X; Chen WM; Li LD; Hao Y; Li JY; Sun K; Zhao XS; Jiang H; Jiang Q; Huang XJ; Qin YZ
Hematol Oncol; 2024 Jan; 42(1):e3251. PubMed ID: 38287528
[TBL] [Abstract][Full Text] [Related]
24. Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1-2 study.
Perl AE; Altman JK; Cortes J; Smith C; Litzow M; Baer MR; Claxton D; Erba HP; Gill S; Goldberg S; Jurcic JG; Larson RA; Liu C; Ritchie E; Schiller G; Spira AI; Strickland SA; Tibes R; Ustun C; Wang ES; Stuart R; Röllig C; Neubauer A; Martinelli G; Bahceci E; Levis M
Lancet Oncol; 2017 Aug; 18(8):1061-1075. PubMed ID: 28645776
[TBL] [Abstract][Full Text] [Related]
25. [Analysis of Clinical Characteristics of Acute B Lymphoblastic Leukemia with EP300-ZNF384 Fusion Gene Positive].
Yao ZL; Li YF; Li M; Li Y; Li WJ; Li HH; Liu YY; Lin SH; Li FW; Zhang J; Jing Y
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2020 Feb; 28(1):24-28. PubMed ID: 32027248
[TBL] [Abstract][Full Text] [Related]
26. Targeting PRMT1-mediated FLT3 methylation disrupts maintenance of MLL-rearranged acute lymphoblastic leukemia.
Zhu Y; He X; Lin YC; Dong H; Zhang L; Chen X; Wang Z; Shen Y; Li M; Wang H; Sun J; Nguyen LX; Zhang H; Jiang W; Yang Y; Chen J; Müschen M; Chen CW; Konopleva MY; Sun W; Jin J; Carlesso N; Marcucci G; Luo Y; Li L
Blood; 2019 Oct; 134(15):1257-1268. PubMed ID: 31395602
[TBL] [Abstract][Full Text] [Related]
27. Gilteritinib is a clinically active FLT3 inhibitor with broad activity against FLT3 kinase domain mutations.
Tarver TC; Hill JE; Rahmat L; Perl AE; Bahceci E; Mori K; Smith CC
Blood Adv; 2020 Feb; 4(3):514-524. PubMed ID: 32040554
[TBL] [Abstract][Full Text] [Related]
28. Prognostic significance of high-level FLT3 expression in MLL-rearranged infant acute lymphoblastic leukemia.
Stam RW; Schneider P; de Lorenzo P; Valsecchi MG; den Boer ML; Pieters R
Blood; 2007 Oct; 110(7):2774-5. PubMed ID: 17881645
[No Abstract] [Full Text] [Related]
29. The European Medicines Agency Review of Gilteritinib (Xospata) for the Treatment of Adult Patients with Relapsed or Refractory Acute Myeloid Leukemia with an FLT3 Mutation.
Tzogani K; Røshol H; Olsen HH; Aas IB; Dalhus ML; Håkonsen GD; Nilssen LS; Lindberg V; Økvist M; Bolstad B; Rogovska I; Karpova N; Enzmann H; Gisselbrecht C; Pignatti F
Oncologist; 2020 Jul; 25(7):e1070-e1076. PubMed ID: 32154636
[TBL] [Abstract][Full Text] [Related]
30. Acute lymphoblastic leukemia with infrequent ARID1B::ZNF384 gene fusion simulating multifocal osteomyelitis.
Long F; Li T; Zhang Y; Gao X; Wang H; Huang X
Pediatr Blood Cancer; 2023 Oct; 70(10):e30514. PubMed ID: 37336773
[No Abstract] [Full Text] [Related]
31. Gilteritinib for the treatment of relapsed and/or refractory FLT3-mutated acute myeloid leukemia.
McMahon CM; Perl AE
Expert Rev Clin Pharmacol; 2019 Sep; 12(9):841-849. PubMed ID: 31454267
[No Abstract] [Full Text] [Related]
32. Pre-B acute lymphoblastic leukaemia recurrent fusion, EP300-ZNF384, is associated with a distinct gene expression.
McClure BJ; Heatley SL; Kok CH; Sadras T; An J; Hughes TP; Lock RB; Yeung D; Sutton R; White DL
Br J Cancer; 2018 Apr; 118(7):1000-1004. PubMed ID: 29531323
[TBL] [Abstract][Full Text] [Related]
33. Clonal Selection with RAS Pathway Activation Mediates Secondary Clinical Resistance to Selective FLT3 Inhibition in Acute Myeloid Leukemia.
McMahon CM; Ferng T; Canaani J; Wang ES; Morrissette JJD; Eastburn DJ; Pellegrino M; Durruthy-Durruthy R; Watt CD; Asthana S; Lasater EA; DeFilippis R; Peretz CAC; McGary LHF; Deihimi S; Logan AC; Luger SM; Shah NP; Carroll M; Smith CC; Perl AE
Cancer Discov; 2019 Aug; 9(8):1050-1063. PubMed ID: 31088841
[TBL] [Abstract][Full Text] [Related]
34. Gilteritinib use in the treatment of relapsed or refractory acute myeloid leukemia with a
Ballesta-López O; Solana-Altabella A; Megías-Vericat JE; Martínez-Cuadrón D; Montesinos P
Future Oncol; 2021 Jan; 17(2):215-227. PubMed ID: 32975130
[TBL] [Abstract][Full Text] [Related]
35. [Clinical characteristics and outcomes of childhood B-ALL with ZNF384 and MEF2D rearrangements].
Hirabayashi S; Manabe A; Ohki K; Kiyokawa N
Rinsho Ketsueki; 2023; 64(7):633-638. PubMed ID: 37544723
[TBL] [Abstract][Full Text] [Related]
36. Gilteritinib Inhibits Glutamine Uptake and Utilization in
Zavorka Thomas ME; Lu X; Talebi Z; Jeon JY; Buelow DR; Gibson AA; Uddin ME; Brinton LT; Nguyen J; Collins M; Lodi A; Sweeney SR; Campbell MJ; Sweet DH; Sparreboom A; Lapalombella R; Tiziani S; Baker SD
Mol Cancer Ther; 2021 Nov; 20(11):2207-2217. PubMed ID: 34518298
[TBL] [Abstract][Full Text] [Related]
37. Identification of the TAF15-ZNF384 fusion gene in two new cases of acute lymphoblastic leukemia with a t(12;17)(p13;q12).
Nyquist KB; Thorsen J; Zeller B; Haaland A; Trøen G; Heim S; Micci F
Cancer Genet; 2011 Mar; 204(3):147-52. PubMed ID: 21504714
[TBL] [Abstract][Full Text] [Related]
38. Understanding gilteritinib resistance to FLT3-F691L mutation through an integrated computational strategy.
Zhou S; Yang B; Xu Y; Gu A; Peng J; Fu J
J Mol Model; 2022 Aug; 28(9):247. PubMed ID: 35932378
